| Symbol | ZLSCF |
|---|---|
| Name | ZYUS LIFE SCIENCES CORP |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | S7N 4L8 Canada SK 407 Downey Road, Unit 204 |
| Telephone | +1 888-651-9987 |
| Fax | — |
| — | |
| Website | https://www.zyus.com/home/default.aspx |
| Incorporation | CA |
| Incorporated On | 2018 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: TSX Venture Exchange |
| CIK | 0001757610 |
| Description | ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and innovative exempt market therapeutics. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP/ EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The ZYUS vision is to elevate cannabinoid-based therapeutics as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients lives around the world. Additional info from OTC: |
No news found.